ELFN1-AS1: A Potential Drug Target or Biomarker for Various Diseases

ELFN1-AS1: A Potential Drug Target or Biomarker for Various Diseases

ELFN1-AS1 (MYCLo-2), a protein that belongs to the ELFN1 gene family, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

ELFN1-AS1 is a 21-kDa protein that is expressed in most tissues of the body, including brain, heart, liver, and muscle. It is a key regulator of cell adhesion and survival, and has been implicated in various physiological processes, including cell signaling, migration, and invasion.

Studies have suggested that ELFN1-AS1 may be involved in the development and progression of several diseases, including cancer. For example, ELFN1-AS1 has been shown to be overexpressed in various types of cancer, and may contribute to the development of cancer by promoting cell survival and promoting the formation of cancerous tissues.

In addition to its potential role in cancer, ELFN1-AS1 has also been suggested as a potential drug target for neurodegenerative diseases. neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neurogenic markers.

ELFN1-AS1 has been shown to be involved in the development and progression of neurodegenerative diseases, and may be a potential drug target or biomarker for these diseases. For example, studies have shown that ELFN1-AS1 can cause neurodegeneration in animal models of Alzheimer's disease, and may also be involved in the development of human neurodegenerative diseases.

In addition to its potential role in neurodegenerative diseases, ELFN1-AS1 has also been suggested as a potential drug target for autoimmune disorders. autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues and causing inflammation and damage.

ELFN1-AS1 has been shown to be involved in the development and progression of autoimmune disorders, and may be a potential drug target or biomarker for these disorders. For example, studies have shown that ELFN1-AS1 can cause inflammation and autoimmune damage in animal models of rheumatoid arthritis, and may also be involved in the development of human autoimmune disorders.

In conclusion, ELFN1-AS1 is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of ELFN1-AS1 in these diseases and to develop effective treatments.

Protein Name: ELFN1 Antisense RNA 1

The "ELFN1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELFN1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE | ENHO